Calypso Medical Technologies, the Seattle-based maker of a system to pinpoint radiation therapy for prostate cancer patients, has taken in another $6.4 million through an offering of debt, options, and other securities, according to a regulatory filing. The company last raised $50 million in venture capital in September 2009. Xconomy last wrote about Calypso in August, when CEO Eric Meier left the company, about 15 percent of the workforce was cut, and its U.S. sales force was reorganized.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
